Zepbound leads to more weight loss than Wegovy, Eli Lilly says
Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than Wegovy, a drug with the main active ingredient semaglutide, according to new data released Wednesday by Eli Lilly, the maker of Zepbound.
Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from ...
Novo Nordisk's team in India has been pushing the Danish drugmaker's global leadership for an earlier launch of its popular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback